Biogen says U.S. FTC, SEC probing Alzheimer's disease drug

The U.S. Federal Trade Commission and the U.S. Securities and Exchange Commission have asked Biogen Inc (BIIB.O) to provide information on the approval and marketing of its new Alzheimer's disease treatment, Aduhelm, the drugmaker disclosed in a filing.